Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice